Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol

BACKGROUND: Adding abiraterone acetate with prednisolone (AAP) or docetaxel with prednisolone (DocP) to standard-of-care (SOC) each improved survival in systemic therapy for advanced or metastatic prostate cancer: evaluation of drug efficacy: a multi-arm multi-stage platform randomised controlled pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Sydes, M R, Spears, M R, Mason, M D, Clarke, N W, Dearnaley, D P, de Bono, J S, Attard, G, Chowdhury, S, Cross, W, Gillessen, S, Malik, Z I, Jones, R, Parker, C C, Ritchie, A W S, Russell, J M, Millman, R, Matheson, D, Amos, C, Gilson, C, Birtle, A, Brock, S, Capaldi, L, Chakraborti, P, Choudhury, A, Evans, L, Ford, D, Gale, J, Gibbs, S, Gilbert, D C, Hughes, R, McLaren, D, Lester, J F, Nikapota, A, O’Sullivan, J, Parikh, O, Peedell, C, Protheroe, A, Rudman, S M, Shaffer, R, Sheehan, D, Simms, M, Srihari, N, Strebel, R, Sundar, S, Tolan, S, Tsang, D, Varughese, M, Wagstaff, J, Parmar, M K B, James, N D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5961425/
https://www.ncbi.nlm.nih.gov/pubmed/29529169
http://dx.doi.org/10.1093/annonc/mdy072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5961425/
https://www.ncbi.nlm.nih.gov/pubmed/29529169
http://dx.doi.org/10.1093/annonc/mdy072

Ejemplares similares